Skip to main content
SpringerLink
Log in

The Role of Chemotherapy and Radiotherapy in Penile Cancer

  • Chapter
  • First Online:
Penile Cancer – A Practical Guide

Part of the book series: Management of Urology ((MU))

Abstract

Chemotherapy and radiation may be used in many instances in the management of penile cancer. Cytotoxic chemotherapy has been used as palliative treatment to prolong life and improve symptoms in metastatic inoperable penile cancer and more recently has moved forward in the therapeutic algorithm as an important perioperative treatment in high risk locally advanced node positive disease. Radiotherapy additionally has an important role in the treatment of the primary lesion and the lymphatic drainage. It is therefore important to involve oncologists early in the pathway of patient treatment and ensure multidisciplinary decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Protzel C, Hakenberg OW. Chemotherapy in patients with penile carcinoma. Urol Int. 2009;82(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  2. Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109(10):2554–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992;147(3):630–2.

    Article  CAS  PubMed  Google Scholar 

  4. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Di Lorenzo G, Carteni G, Autorino R, Gonnella A, Perdona S, Ferro M, et al. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anti-Cancer Drugs. 2009;20(4):277–80.

    Article  PubMed  Google Scholar 

  6. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007;177(4):1335–8.

    Article  PubMed  Google Scholar 

  7. Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–50.

    Article  PubMed  Google Scholar 

  8. Castiglione F, Alnajjar HM, Christodoulidou M, Albersen M, Parnham A, Freeman A, et al. Primary squamous cell carcinoma of the male proximal urethra: outcomes from a single centre. Eur Urol Focus. 2021;7(1):163–9.

    Article  PubMed  Google Scholar 

  9. Cakir OO, Castiglione F, Tandogdu Z, Collins J, Alnajjar HM, Akers C, et al. Management of penile cancer patients during the COVID-19 pandemic: an eUROGEN accelerated Delphi consensus study. Urol Oncol. 2021;39(3):197. e9- e17

    Article  PubMed Central  Google Scholar 

  10. Canter DJ, Nicholson S, Watkin N, Hall E, Pettaway C, In PEC. The international penile advanced cancer trial (InPACT): rationale and current status. Eur Urol Focus. 2019;5(5):706–9.

    Article  PubMed  Google Scholar 

  11. Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol. 1997;32(1):5–15.

    Article  CAS  PubMed  Google Scholar 

  12. Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98(6):1225–7.

    Article  CAS  PubMed  Google Scholar 

  13. Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol. 2015;33(11):496. e17-23

    Article  Google Scholar 

  14. Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, et al. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA Oncol. 2018;4(5):643–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BFP, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol. 2017;59:55–61.

    Article  CAS  PubMed  Google Scholar 

  16. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.

    Article  CAS  PubMed  Google Scholar 

  17. Chahoud J, Skelton WPT, Spiess PE, Walko C, Dhillon J, Gage KL, et al. Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab. Front Oncol. 2020;10:615298.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, et al. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Investig New Drugs. 2021;39(5):1405–10.

    Article  CAS  Google Scholar 

  19. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–8.

    Article  CAS  PubMed  Google Scholar 

  20. Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol. 2007;177(3):947–52. discussion 52

    Article  PubMed  Google Scholar 

  21. Ornellas AA, Seixas AL, Marota A, Wisnescky A, Campos F, de Moraes JR. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol. 1994;151(5):1244–9.

    Article  CAS  PubMed  Google Scholar 

  22. Ravi R. Morbidity following groin dissection for penile carcinoma. Br J Urol. 1993;72(6):941–5.

    Article  CAS  PubMed  Google Scholar 

  23. Crook JM, Haie-Meder C, Demanes DJ, Mazeron JJ, Martinez AA, Rivard MJ. American Brachytherapy Society-Groupe Europeen de Curietherapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy. 2013;12(3):191–8.

    Article  PubMed  Google Scholar 

  24. Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol. 2003;170(2 Pt 1):359–65.

    Article  PubMed  Google Scholar 

  25. Ozsahin M, Jichlinski P, Weber DC, Azria D, Zimmermann M, Guillou L, et al. Treatment of penile carcinoma: to cut or not to cut? Int J Radiat Oncol Biol Phys. 2006;66(3):674–9.

    Article  PubMed  Google Scholar 

  26. Robinson R, Marconi L, MacPepple E, Hakenberg OW, Watkin N, Yuan Y, et al. Risks and benefits of adjuvant radiotherapy after inguinal lymphadenectomy in node-positive penile cancer: a systematic review by the European Association of Urology penile cancer guidelines panel. Eur Urol. 2018;74(1):76–83.

    Article  PubMed  Google Scholar 

  27. Ager M, Njoku K, Serra M, Robinson A, Pickering L, Afshar M, et al. Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU Int. 2021;128(4):451–9.

    Article  CAS  PubMed  Google Scholar 

  28. Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2011;186(2):524–9.

    Article  PubMed  Google Scholar 

  29. Van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A, Kataja V, et al. Penile cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi115-24.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Services, University College London Hospitals NHS Foundation Trust, London, UK

    Constantine Alifrangis & Anita Mitra

Authors
  1. Constantine Alifrangis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita Mitra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constantine Alifrangis .

Editor information

Editors and Affiliations

  1. King’s College London, London, UK

    Oliver Brunckhorst

  2. King’s College London, London, UK

    Kamran Ahmed

  3. University College London Hospital and University College London, London, UK

    Asif Muneer

  4. University College London Hospital and University College London, London, UK

    Hussain M Alnajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alifrangis, C., Mitra, A. (2023). The Role of Chemotherapy and Radiotherapy in Penile Cancer. In: Brunckhorst, O., Ahmed, K., Muneer, A., Alnajjar, H.M. (eds) Penile Cancer – A Practical Guide. Management of Urology. Springer, Cham. https://doi.org/10.1007/978-3-031-32681-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-32681-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-32680-6

  • Online ISBN: 978-3-031-32681-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation